The liquid biopsy market is estimated at USD 4.03 billion in 2025 and is projected to reach USD 7.05 billion by 2030, growing at a CAGR of 11.8% during the forecast period. The liquid biopsy market is witnessing strong growth due to the rising global burden of cancer and increasing awareness of the importance of early detection, supported by initiatives from leading health organizations.
Liquid biopsy provides several advantages over traditional tissue biopsy procedures, including being minimally invasive, offering faster results, and allowing real-time monitoring of disease progression and treatment response. These benefits make liquid biopsy an increasingly preferred option for both clinicians and patients
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Liquid Biopsy Market Dynamics:
Drivers:
1. Rising incidence and prevalence of cancer 2. Cancer awareness initiatives undertaken by global health organizations 3. Benefits of liquid biopsy over traditional biopsy procedures
Restraints:
1. Lower sensitivity of certain liquid biopsy procedures
Opportunities:
1. Growing significance of companion diagnostics 2. Growth opportunities in emerging countries
Challenge:
1. Unclear reimbursement scenario
Key Market Players of Liquid Biopsy Industry:
The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).
Natera, Inc. (US) focuses heavily on R&D capabilities to enhance its portfolio of cell-free DNA-based tests to improve clinical decision-making across oncology, transplant, and reproductive health. Its investments in R&D and capital allocation strategies help fuel its future growth and ability to remain competitive. The company’s strategies, including collaborations and acquisitions, aim to solidify its liquid biopsy market position further.
Guardant Health (US) holds a significant share in the liquid biopsy market, supported by its broad distribution network spanning the Americas, Europe, the Middle East & Africa, and Asia Pacific. The company maintains a strong market presence by offering innovative, high-quality products across the entire value chain. Guardant Health emphasizes research and development and pursues organic growth strategies to reinforce its market position. For instance, in June 2025, the company’s Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the US FDA. This blood-based test utilizes methylation analysis to detect various cancers, including bladder, colorectal, lung, and pancreatic, in individuals aged 45 and older at average risk.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html